Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
MWN-AI** Summary
Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company focused on developing innovative peptide conjugate therapeutics, has announced a 1-for-12 reverse stock split set to take effect at 5:00 p.m. ET on March 6, 2026. Following the split, which is aimed at regaining compliance with Nasdaq's minimum closing bid price requirement of $1.00, Decoy's common stock will trade under a new CUSIP number 79400X602 beginning March 9, 2026.
The decision for the reverse split was approved by Decoy's stockholders during a special meeting on February 24, 2026. The Board of Directors determined that the 1-for-12 ratio was appropriate, reducing the number of outstanding shares from approximately 6.38 million to roughly 532,000. This maneuver is intended to enhance the company's stock price and improve its market standing without affecting the overall ownership percentages of existing stockholders, although fractional shares will be compensated in cash.
Equiniti Trust Company, LLC, will serve as the exchange agent for the reverse split, providing instructions for stockholders on exchanging their pre-split certificates for post-split shares. Notably, the reverse split does not alter the number of authorized shares or the par values of common or preferred stock.
Decoy Therapeutics is actively working on drug candidates targeting respiratory viruses and gastrointestinal cancers, leveraging advanced machine learning and synthesis techniques. The company has gained substantial support from investors and various grants, reinforcing its commitment to addressing serious medical needs. As it navigates this corporate restructuring, Decoy remains focused on executing its development plans despite the inherent risks of the biopharmaceutical landscape.
MWN-AI** Analysis
Decoy Therapeutics Inc.'s recent announcement of a 1-for-12 reverse stock split comes in response to its need to maintain compliance with Nasdaq’s minimum bid-price requirement. This strategic maneuver could create a mixed sentiment in the market, offering both potential risks and opportunities for investors.
On one hand, a reverse stock split can often be seen as a red flag, signaling potential financial distress. It typically aims to increase the stock price per share, though it doesn’t improve the company’s overall market capitalization or solve underlying business challenges. Investors should be cautious; while a higher share price may help attract new investors, it does not change the fundamentals of Decoy’s operations or financial health.
On the other hand, for investors willing to engage with risk, Decoy’s focus on developing innovative peptide conjugate therapeutics may present opportunities. The company operates in a high-stakes industry with significant growth potential, particularly if its drug candidates targeting respiratory viruses and gastrointestinal cancers yield positive clinical results. Partnerships and funding from reputable sources, including the Massachusetts Life Sciences Seed Fund and corporate entities like Google AI and NVIDIA, bolster its credibility and prospects.
Going forward, investors should closely monitor Decoy’s clinical trial progress and financial performance post-split, as these will provide insight into whether the company can capitalize on its scientific advancements. Additionally, considering the historical context of biotech companies performing well after reverse splits can inform investment timing. Meanwhile, risk-averse investors may want to stay on the sidelines until further clarity emerges regarding Decoy's operational stability and market position post-split. Overall, careful analysis and a tailored approach to portfolio diversification are recommended in light of the upcoming changes.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics, today announced that it will effect a 1-for-12 reverse stock split at 5:00 p.m. Eastern Time, on March 6, 2026. Beginning with the opening of trading on March 9, 2026, Decoy's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X602.
The reverse stock split is intended to enable Decoy to regain compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market.
At a special meeting of stockholders held on February 24, 2026, Decoy's stockholders approved the proposal to authorize Decoy's Board of Directors to file an amendment to Decoy's amended and restated certificate of incorporation ("Certificate of Incorporation") to effect the reverse split at a ratio to be determined by the Board, ranging from 1-for-4 to 1-for-15. The specific 1-for-12 ratio was subsequently approved by Decoy's Board of Directors and the reverse stock split will be effected by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware.
The reverse split will affect all issued and outstanding shares of Decoy's common stock. At the effective time of the reverse stock split the number of shares of common stock issued and outstanding will be reduced from approximately 6.38 million shares to approximately 532,000 shares. All outstanding options and warrants entitling their holders to purchase shares of Decoy's common stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares reserved for future issuance pursuant to Decoy's 2015 Equity Incentive Plan and Employee Stock Purchase Plan will also be appropriately adjusted. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of Decoy's shares (except to the extent that the reverse stock split would result in some of the stockholders receiving cash in lieu of fractional shares). Stockholders will receive cash in lieu of fractional shares based on the closing price per share of Decoy's common stock as quoted on the Nasdaq Capital Market on March 6, 2026. The reverse stock split will not reduce the number of authorized shares of common stock or preferred stock or change the par values of Decoy's common stock (which will remain at $0.0001 per share) or preferred stock (which will remain at $0.0001 per share).
Equiniti Trust Company, LLC, ("Equiniti") is acting as the exchange agent and transfer agent for the reverse stock split. Equiniti will provide instructions to stockholders with physical certificates regarding the process for exchanging their pre-split stock certificates for post-split shares in book-entry form and receiving payment for any fractional shares.
Additional information about the reverse stock split can be found in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission ("SEC") on January 9, 2026. The Proxy Statement is available at www.sec.gov or on Decoy's website at decoytx.com.
About Decoy Therapeutics Inc.
Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the Biomedical Advanced Research and Development Authority (BARDA) through BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Current Report on Form 8-K filed on August 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.
SOURCE Decoy Therapeutics, Inc
FAQ**
How will the 1-for-reverse stock split on Decoy Therapeutics Inc Com Par $0.0001 (New) DCOY impact the market perception of the company’s financial health and its ability to attract future investments?
What measures is Decoy Therapeutics Inc Com Par $0.0001 (New) DCOY implementing to ensure that the reverse stock split leads to improved compliance with Nasdaq's listing requirements?
In light of the reverse stock split, how does the management of Decoy Therapeutics Inc Com Par $0.0001 (New) DCOY plan to communicate the potential future growth and developments of its peptide conjugate therapeutics pipeline to its shareholders?
What are the anticipated impacts of this reverse stock split on the trading liquidity of Decoy Therapeutics Inc Com Par $0.0001 (New) DCOY, particularly concerning institutional investor interest and retail trader participation?
**MWN-AI FAQ is based on asking OpenAI questions about Decoy Therapeutics Inc Com Par $0.0001 (New) (NASDAQ: DCOY).
NASDAQ: DCOY
DCOY Trading
-0.24% G/L:
$8.48 Last:
21,988 Volume:
$8.47 Open:
